HUP0302884A2 - Módszer hepatocitába való gyógyszerbejuttatásra és flaviridae fertőzések kezelésére - Google Patents
Módszer hepatocitába való gyógyszerbejuttatásra és flaviridae fertőzések kezeléséreInfo
- Publication number
- HUP0302884A2 HUP0302884A2 HU0302884A HUP0302884A HUP0302884A2 HU P0302884 A2 HUP0302884 A2 HU P0302884A2 HU 0302884 A HU0302884 A HU 0302884A HU P0302884 A HUP0302884 A HU P0302884A HU P0302884 A2 HUP0302884 A2 HU P0302884A2
- Authority
- HU
- Hungary
- Prior art keywords
- drug
- treatment
- hepatocytes
- methods
- drug delivery
- Prior art date
Links
- 208000004576 Flaviviridae Infections Diseases 0.000 title 1
- 238000012377 drug delivery Methods 0.000 title 1
- 210000003494 hepatocyte Anatomy 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 7
- 229940079593 drug Drugs 0.000 abstract 6
- 210000005229 liver cell Anatomy 0.000 abstract 4
- 210000000170 cell membrane Anatomy 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 230000032258 transport Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 229960000329 ribavirin Drugs 0.000 abstract 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22686900P | 2000-08-22 | 2000-08-22 | |
| US24062700P | 2000-10-13 | 2000-10-13 | |
| PCT/US2001/026057 WO2002015904A1 (en) | 2000-08-22 | 2001-08-21 | Methods of drug delivery to hepatocytes and treatment of flaviviridae infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUP0302884A2 true HUP0302884A2 (hu) | 2003-12-29 |
Family
ID=26920944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0302884A HUP0302884A2 (hu) | 2000-08-22 | 2001-08-21 | Módszer hepatocitába való gyógyszerbejuttatásra és flaviridae fertőzések kezelésére |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1313469A1 (zh) |
| JP (1) | JP2004506684A (zh) |
| KR (1) | KR20030040416A (zh) |
| CN (1) | CN1447692A (zh) |
| AU (1) | AU2001292557A1 (zh) |
| BR (1) | BR0113388A (zh) |
| CA (1) | CA2415793A1 (zh) |
| CZ (1) | CZ2003308A3 (zh) |
| HU (1) | HUP0302884A2 (zh) |
| IL (1) | IL154167A0 (zh) |
| MX (1) | MXPA03001529A (zh) |
| NO (1) | NO20030794L (zh) |
| PL (1) | PL365744A1 (zh) |
| RU (1) | RU2003102607A (zh) |
| WO (1) | WO2002015904A1 (zh) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003037908A1 (en) * | 2001-10-31 | 2003-05-08 | Ribapharm Inc. | Antiviral combination therapy and compositions |
| US6811777B2 (en) * | 2002-04-13 | 2004-11-02 | Allan Mishra | Compositions and minimally invasive methods for treating incomplete connective tissue repair |
| US7608258B2 (en) | 2002-04-13 | 2009-10-27 | Allan Mishra | Method for treatment of tendinosis using platelet rich plasma |
| US20050182252A1 (en) | 2004-02-13 | 2005-08-18 | Reddy K. R. | Novel 2'-C-methyl nucleoside derivatives |
| US20100112081A1 (en) | 2008-10-07 | 2010-05-06 | Bioparadox, Llc | Use of platelet rich plasma composition in the treatment of cardiac conduction abnormalities |
| US20140356893A1 (en) | 2013-06-04 | 2014-12-04 | Allan Mishra | Compositions and methods for using platelet-rich plasma for drug discovery, cell nuclear reprogramming, proliferation or differentiation |
| JP2017512183A (ja) | 2014-02-13 | 2017-05-18 | リガンド・ファーマシューティカルズ・インコーポレイテッド | プロドラッグ化合物およびそれらの使用 |
| CN106687118A (zh) | 2014-07-02 | 2017-05-17 | 配体药物公司 | 前药化合物及其用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3984396A (en) * | 1971-06-01 | 1976-10-05 | Icn Pharmaceuticals, Inc. | 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters |
| US5959077A (en) * | 1993-05-26 | 1999-09-28 | Laboratori Balducci S.P.A. | Hepatotropic conjugates of antiviral drugs carriers thereof and pharmaceutical compositions containing them |
-
2001
- 2001-08-21 AU AU2001292557A patent/AU2001292557A1/en not_active Abandoned
- 2001-08-21 EP EP01972926A patent/EP1313469A1/en not_active Withdrawn
- 2001-08-21 HU HU0302884A patent/HUP0302884A2/hu unknown
- 2001-08-21 PL PL01365744A patent/PL365744A1/xx unknown
- 2001-08-21 IL IL15416701A patent/IL154167A0/xx unknown
- 2001-08-21 CN CN01814399A patent/CN1447692A/zh active Pending
- 2001-08-21 KR KR10-2003-7002539A patent/KR20030040416A/ko not_active Application Discontinuation
- 2001-08-21 BR BR0113388-8A patent/BR0113388A/pt not_active IP Right Cessation
- 2001-08-21 WO PCT/US2001/026057 patent/WO2002015904A1/en not_active Application Discontinuation
- 2001-08-21 JP JP2002520825A patent/JP2004506684A/ja not_active Withdrawn
- 2001-08-21 CZ CZ2003308A patent/CZ2003308A3/cs unknown
- 2001-08-21 MX MXPA03001529A patent/MXPA03001529A/es unknown
- 2001-08-21 CA CA002415793A patent/CA2415793A1/en not_active Abandoned
- 2001-08-21 RU RU2003102607/15A patent/RU2003102607A/ru not_active Application Discontinuation
-
2003
- 2003-02-20 NO NO20030794A patent/NO20030794L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1313469A1 (en) | 2003-05-28 |
| JP2004506684A (ja) | 2004-03-04 |
| NO20030794D0 (no) | 2003-02-20 |
| BR0113388A (pt) | 2004-02-25 |
| MXPA03001529A (es) | 2004-04-02 |
| RU2003102607A (ru) | 2004-07-27 |
| CZ2003308A3 (cs) | 2004-03-17 |
| KR20030040416A (ko) | 2003-05-22 |
| AU2001292557A1 (en) | 2002-03-04 |
| IL154167A0 (en) | 2003-07-31 |
| CN1447692A (zh) | 2003-10-08 |
| NO20030794L (no) | 2003-04-22 |
| WO2002015904A1 (en) | 2002-02-28 |
| WO2002015904B1 (en) | 2002-07-04 |
| PL365744A1 (en) | 2005-01-10 |
| CA2415793A1 (en) | 2002-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY141025A (en) | Dose forms | |
| WO2007089618A3 (en) | Hepatitis c serine protease inhibitors and uses therefor | |
| PL371736A1 (en) | Method for administering glp-1 molecules | |
| NO20062504L (no) | Sammensetninger og doseringsformer for forbedret absorpsjon | |
| TW200633718A (en) | Treatment of hepatitis c in the asian population | |
| NO20080351L (no) | Anvendelse av sanglifehrin i HCV | |
| MX2007004025A (es) | Uso de derivados del acido nordihidroguaiaretico en el tratamiento de cancer e infecciones microbial y viral resistente a farmacos._. | |
| UA88440C2 (ru) | ЛЕЧЕНИЕ ГЛОМЕРУЛОНЕФРИТА И ХРОНИЧЕСКОЙ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ ПРИ ПОМОЩИ ИНТЕРФЕРОНА-β | |
| IL174787A0 (en) | Use of cell lines to produce active therapeutic proteins | |
| MX2009012598A (es) | Formas de dosis que comprenden vx-950 y su regimen de dosificacion. | |
| Ouwerkerk-Mahadevan et al. | No clinically significant interaction between the investigational HCV protease inhibitor TMC435 and the immunosuppressives cyclosporine and tacrolimus: 80 | |
| HUP0302884A2 (hu) | Módszer hepatocitába való gyógyszerbejuttatásra és flaviridae fertőzések kezelésére | |
| ATE433459T1 (de) | Desoxo-nonadepsipeptide | |
| NO20091628L (no) | Kombinasjonsmedikament | |
| NO20055512L (no) | Terapi eller prevensjon av respiratoriske, virale infeksjoner med alfa-tyimosinpeptider | |
| MD20060037A (ro) | Metodă de tratament al hepatitei virale acute C | |
| RS20050255A (en) | Therapies for chronic inflammatory demyelinating polyneuropathy using interferon-betha | |
| Liu et al. | Combination treatments with hydroxychloroquine and azithromycin are compatible with the therapeutic induction of anticancer immune responses | |
| NO20080495L (no) | PEG-IFN-alfa og ribavirin for HBV-behandling | |
| MD3121F1 (en) | Method of viral hepatitis B prophylaxis | |
| DE602005011029D1 (de) | Therapeutisches mittel zur behandlung von plasmazellneoplasien | |
| ATE544453T1 (de) | Kombinationstherapien mit l-fmau zur behandlung von hepatitis-b-virus-infektionen | |
| Poordad et al. | Low Relapse Rate Leads to High Concordance of SVR4 and SVR12 with SVR24 After Treatment with ABT-450/r, ABT-267, ABT-333+ Ribavirin in Patients with Chronic HCV Genotype 1 Infection in the AVIATOR Study: 1089 | |
| UA103907C2 (ru) | Терапевтический режим лечения гепатита, который включает пег-интерферон, рибавирин и vx-950 | |
| Tan et al. | Analysis of ALS-2200, a Novel Potent Nucleotide Analog, Combination Drug Interactions in the Hepatitis C Virus (HCV) Subgenomic Replicon System: 1887 |